Moreover, the 36-month beta value for IOBT is 0.35. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for IOBT is 44.87M and currently, short sellers hold a 0.45% of that float. On November 13, 2024, IOBT’s average trading volume was 455.00K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
IOBT) stock’s latest price update
The stock price of IO Biotech Inc (NASDAQ: IOBT) has dropped by -11.68 compared to previous close of 1.05. Despite this, the company has seen a fall of -19.36% in its stock price over the last five trading days. globenewswire.com reported 2024-11-12 that Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced melanoma on track with primary endpoint of progression free survival (PFS) projected to be reached in first half of 2025 Primary endpoint met in Phase 2 basket trial (IOB-022/KN-D38) cohort evaluating IO102-IO103 in combination with pembrolizumab in the first-line treatment of advanced squamous cell carcinoma of the head and neck (SCCHN) Enrollment in Phase 2 basket trial (IOB-032/PN-E40) evaluating IO102-IO103 in combination with pembrolizumab as neoadjuvant and adjuvant treatment of patients with resectable melanoma or SCCHN is proceeding ahead of schedule Ended third quarter with approximately $80 million in cash and cash equivalents; the company continues to expect its cash position will support operations into the fourth quarter of 2025 NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today reported financial results for the third quarter ended September 30, 2024. “We continue to add to the body of evidence that our novel investigational therapeutic cancer vaccine, IO102-IO103, has the potential to bring clinical benefit to patients with strong signals of activity now observed in patients with three types of metastatic solid tumors,” said Mai-Britt Zocca, PhD, President and CEO of IO Biotech.
IOBT’s Market Performance
IO Biotech Inc (IOBT) has experienced a -19.36% fall in stock performance for the past week, with a -20.05% drop in the past month, and a -33.76% drop in the past quarter. The volatility ratio for the week is 16.80%, and the volatility levels for the past 30 days are at 9.35% for IOBT. The simple moving average for the past 20 days is -22.30% for IOBT’s stock, with a -32.54% simple moving average for the past 200 days.
IOBT Trading at -15.03% from the 50-Day Moving Average
After a stumble in the market that brought IOBT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.80% of loss for the given period.
Volatility was left at 9.35%, however, over the last 30 days, the volatility rate increased by 16.80%, as shares sank -22.07% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.26% lower at present.
During the last 5 trading sessions, IOBT fell by -19.36%, which changed the moving average for the period of 200-days by -49.60% in comparison to the 20-day moving average, which settled at $1.1936. In addition, IO Biotech Inc saw -50.67% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IOBT starting from Novo Holdings A/S, who proposed sale 1,000,000 shares at the price of $0.84 back on Sep 11 ’24. After this action, Novo Holdings A/S now owns shares of IO Biotech Inc, valued at $844,000 using the latest closing price.
Novo Holdings A/S, the 10% Owner of IO Biotech Inc, sale 51,522 shares at $1.33 during a trade that took place back on Jul 25 ’24, which means that Novo Holdings A/S is holding 4,377,927 shares at $68,339 based on the most recent closing price.
Stock Fundamentals for IOBT
Current profitability levels for the company are sitting at:
- -84.14 for the present operating margin
- 0.26 for the gross margin
The net margin for IO Biotech Inc stands at -79.28. The total capital return value is set at -0.96. Equity return is now at value -87.66, with -76.85 for asset returns.
Based on IO Biotech Inc (IOBT), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -119.03. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -72.63.
Currently, EBITDA for the company is -91.23 million with net debt to EBITDA at 1.11. When we switch over and look at the enterprise to sales, we see a ratio of -33.78. The receivables turnover for the company is 1.08for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.84.
Conclusion
To wrap up, the performance of IO Biotech Inc (IOBT) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
